Skin Diseases  >>  Erbitux (cetuximab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erbitux (cetuximab) / Eli Lilly, EMD Serono
DIPROCOL, NCT00910676 / 2007-002913-38: Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors

Completed
2
30
Europe
Diprosone
Centre Oscar Lambret, Roche Pharma AG
Metastatic Colorectal Cancer, Non-Small-Cell Lung Carcinoma
03/09
03/09
NCT00232505: Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Completed
2
112
US
cetuximab, Erbitux, carboplatin, Paraplatin
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI), Bristol-Myers Squibb, Avon Foundation, National Center for Research Resources (NCRR)
Breast Cancer
06/10
08/12
NCT00633464: Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Completed
2
79
Europe
ixabepilone, IXEMPRA, BMS-247550, ixabepilone + cetuximab, ERBITUX, BMS-564717
R-Pharm
Triple Negative Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer
09/10
05/11
NCT00600249 / 2007-002371-13: Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Checkmark ASCO-2013
May 2013 - May 2013: ASCO-2013
Completed
2
35
Europe
Cetuximab, Current sponsor code: EMD271786, Docetaxel, CAS: 148408-66-6
Centre Jean Perrin, Merck Sharp & Dohme LLC, Sanofi
Breast Cancer
05/12
05/12

Download Options